News
-
Results From Five Phase III Studies Presented For GSK’s Two Candidate Quadrivalent Influenza Vaccines
10/22/2012
GlaxoSmithKline plc (GSK) recently announced that results from five Phase III studies investigating its two candidate quadrivalent influenza vaccines (QIVs) were presented at the Influenza Vaccines for the World (IVW) congress in Valencia, Spain and the Infectious Diseases week (IDweek) congress in San Diego, USA in October.
-
Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease
10/22/2012
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease (CD).
-
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension
10/12/2012
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
-
Aeras Signs Agreement With GSK To Jointly Advance TB Vaccine
10/10/2012
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK’s proprietary M72 antigen and AS01E adjuvant.
-
Novavax Initiates Phase 2 Clinical Trial Of RSV Vaccine Candidate
10/8/2012
Novavax, Inc. today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.
-
VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration For Development Of Novel TLR8 Agonist VTX-2337 With Celgene Corporation
10/3/2012
VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG) for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.
-
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
9/21/2012
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20.
-
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration With AstraZeneca
9/10/2012
Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.
-
Merck Announces New Phase III Data For Suvorexant, An Investigational Insomnia Medicine
9/10/2012
Merck, known as MSD outside the United States and Canada, recently announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
-
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
9/5/2012
Pluristem Therapeutics, Inc. a leading developer of placenta-based cell therapies, announced recently that the Company’s Placental eXpanded (PLX) cells were successfully administered to a third patient at Hadassah Medical Center, following two other life saving compassionate use cases.